Condition: Colorectal Adenoma · Probiotics · Sponsor: The Affiliated Hospital of Qingdao University
The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.
This description comes directly from the study's public registry record.
Gan Liu · +86 18866799842 · docliu163@163.com
yanbing Zhou · +86 0532-82911324 · zhouyanbing@qduhospital.cn
Always discuss trial participation with your own doctor first.
| the Affiliated Hospital of QIngdao University | Qingdao, Shandong, China | Recruiting |
| Weifang People's Hospital | Weifang, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07167342